1921
Volume 78, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Melioidosis is an infectious disease endemic to northern Australia and Southeast Asia. In response to clinical confusion regarding the appropriate dose of amoxicillin-clavulanate, we have developed guidelines for the appropriate dosing of this second-line agent. For eradication therapy for melioidosis, we recommend 20/5 mg/kg orally, three times daily.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.78.208
2008-02-01
2017-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/78/2/0780208.html?itemId=/content/journals/10.4269/ajtmh.2008.78.208&mimeType=html&fmt=ahah

References

  1. Cheng AC, Currie BJ, 2005. Melioidosis: epidemiology, patho-physiology, and management. Clin Microbiol Rev 18 : 383–416.
  2. Peacock SJ, 2006. Melioidosis. Curr Opin Infect Dis 19 : 421–428.
  3. Centers for Disease Control and Prevention, 2004. Laboratory exposure to Burkholderia pseudomallei—Los Angeles, California, 2003. MMWR Morb Mortal Wkly Rep 53 : 988–990.
  4. Gilbert D, Moellering R, Eliopolous G, Sande M, 2006. The Sanford Guide to Antimicrobial Therapy 2006. Sperryville, VA: Antimicrobial Therapy.
  5. Arzola JM, Hawley JS, Oakman C, Mora RV, 2007. A case of prostatitis due to Burkholderia pseudomallei. Nat Clin Pract Urol 4 : 111–114.
  6. Lee YL, Lee SS, Tsai HC, Chen YS, Wann SR, Kao CH, Liu YC, 2006. Pyogenic liver abscess caused by Burkholderia pseudomallei in Taiwan. J Formos Med Assoc 105 : 689–693.
  7. White NJ, 2003. Melioidosis. Lancet 361 : 1715–1722.
  8. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, Dance DA, Smith MD, Wuthiekanun V, Walsh AL, Pukrittayakamee S, White NJ, 1994. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 19 : 846–853.
  9. Dance DA, Wuthiekanun V, Chaowagul W, White NJ, 1989. The activity of amoxycillin/clavulanic acid against Pseudomonas pseudomallei. J Antimicrob Chemother 24 : 1012–1014.
  10. Chierakul W, Wangboonskul J, Singtoroj T, Pongtavornpinyo W, Short JM, Maharjan B, Wuthiekanun V, Dance DA, Teparrukkul P, Lindegardh N, Peacock SJ, Day NP, Chaowagul W, White NJ, 2006. Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. J Antimicrob Chemother 58 : 1215–1220.
  11. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DAB, White NJ, 1995. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 89 : 546–549.
  12. Limmathurotsakul D, Chaowagul W, Chierakul W, Stepniewska K, Maharjan B, Wuthiekanun V, White NJ, Day NP, Peacock SJ, 2006. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 43 : 979–986.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.78.208
Loading
  • Received : 13 Jun 2007
  • Accepted : 28 Jul 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error